RESEARCH ARTICLE

The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis

Gláucia Fernandes Cota1*, Marcos Roberto de Sousa2*, Tatiani Oliveira Fereguetti3†, Priscila Said Saleme3†, Thais Kawagoe Alvarisa3†, Ana Rabello1‡

1 Clinical Research and Public Policy in Infectious and Parasitic Diseases, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Fiocruz, Belo Horizonte, Minas Gerais, Brazil, 2 Post-Graduate Program in Adult Health Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 3 Hospital Eduardo de Menezes, Fundação Hospitalar do Estado de Minas Gerais-FHEMIG, Belo Horizonte, Minas Gerais, Brazil

* These authors contributed equally to this work.
† These authors also contributed equally to this work.
‡ cota@cpqrr.fiocruz.br

Abstract

Introduction

There are few drugs with proven efficacy in cutaneous leishmaniasis (CL), and pentavalent antimonial derivatives are still the main first-line therapeutic agents worldwide, despite their recognized high toxicities. Randomized controlled clinical trials assessing the efficacy and safety of new therapeutic modalities are of high priority, and the definition of the design of such trials raises debate about the use of placebo as a comparator. To support the use of placebo as a comparator, two main points need to be addressed: 1- the cure rate without any therapeutic intervention and 2- the damage caused by CL and its impact on patients.

Objective

The aim of this study was to systematically assess the spontaneous cure rate for American CL and to broaden the discussion about placebo use in CL trials.

Methods

The PRISMA guidelines for systematic reviews and the Cochrane manual were followed. The sources used were the PubMed and LILACS databases. Studies were included if they reported cure rates using placebo or no treatment in American CL.

Results

Thirteen studies of a total of 352 patients were ultimately included in this review. The summarized global cure rates for all Leishmania species according to the intention-to-treat analyses performed at approximately three (“initial cure”) and nine (“definitive cure”) months after “no treatment” or placebo use were 26% (CI95%: 16 to 40%) and 26% (CI95%:16 to 38%), respectively. Notably, a significantly lower cure rate was observed for L. braziliensis...
infection (6.4%, CI95%:0.2 to 20%) than for \textit{L. mexicana} infection (44%, CI95%:19 to 72%), \( p = 0.002 \). Of note, relapse occurred in 20% of patients with initial healing (CI95%:9.2 to 38.9%).

**Conclusion**

These results clearly demonstrate a low spontaneous cure rate following no-treatment or placebo use, confirming that this strategy for the control group in CL studies expose patients to greater morbidity, especially for CL caused by \textit{L. braziliensis}. Therefore, from this point, the crucial question to consider regarding placebo use is the seriousness of the suffering caused by this disease.

**Introduction**

Cutaneous leishmaniasis (CL) is considered one of the most neglected and serious parasitic infectious skin diseases in many developing countries. Infectious diseases can be considered neglected “when there is a lack of effective, affordable, or easy to use drug treatments” [1].

The current recommendations for CL treatment are generally weak, as the quality of the supporting evidence for such treatments is generally inadequate [2, 3]. Although three major systematic reviews [4–6] have shown that treatment with antimonial derivatives was superior to the other options available, their low cure rate (76.5%) [6] and the recognized toxicity of antimonial derivatives clearly indicate the urgent need for better treatment alternatives. Moreover, high-quality clinical trials testing new treatment modalities with reliable evidence of efficacy, safety, tolerability and effectiveness are absolutely necessary.

In addition to being scientifically valid, clinical trials must be ethical and minimize the risks to which the research participants are exposed. In the case of CL, to understand the risks that participants of studies that compare different interventions are exposed to, the spontaneous cure rates for CL caused by each species of \textit{Leishmania} in different endemic regions must be determined. Based on a non-systematic literature observation, the spontaneous healing trend reported in the Old World—especially with \textit{L. major} infection[7]—is far lower than that observed among American CL patients (for CL caused by organisms of the \textit{L. mexicana} complex and \textit{Viannia} sub-genus—the \textit{L. braziliensis} and \textit{L. guyanensis} complexes). This suggests that the frequency of spontaneous healing observed for one species should not be generalized to other species. The aim of this study was to systematically assess the rate of spontaneous cure in American CL to support the planning of future clinical studies with regard to statistical parameters and placebo use in the Americas.

**Data sources and study selection**

The review methodology followed the recommendations of the PRISMA guidelines [8] for systematic reviews (S1 Text) and the recommendations of the Cochrane Collaboration Group [9]. We searched PubMed and Lilacs, the free access bases, with no language restriction from inception through March, 2015 to identify all studies that described the rate of spontaneous cure in American CL. Studies were included if they reported CL cure rates with placebo or no treatment in individuals living in the Americas. The search was planned independently by two reviewers (GFC and MRS) who proposed three different strategies for PubMed database: (i) a comprehensive strategy, (ii) a strategy directed at the “placebo” term and (iii) a strategy using all narrative and systematic reviews on the subject as the basis. Study selection was made...
independently by four reviewers (GFC, TFO, PSS, and TKA), and any disagreement was resolved by consensus. In the first strategy, we used a combination of the following keywords: "leishmaniasis, cutaneous" [MeSH Terms] OR ("leishmaniasis"[All Fields] AND "cutaneous"[All Fields]) OR ("cutaneous leishmaniasis" [All Fields] OR ("leishmaniasis" [All Fields] AND "cutaneous"[All Fields]) OR "leishmaniasis, cutaneous" [All Fields] AND ("drug therapy"[Subheading] OR "drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "drug therapy" [MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All Fields]) AND "humans" [MeSH Terms]. In the second strategy, we used a combination of the following keywords: "leishmaniasis, cutaneous" [MeSH Terms] OR ("leishmaniasis"[All Fields] AND "cutaneous"[All Fields]) OR "cutaneous leishmaniasis"[All Fields] OR ("leishmaniasis"[All Fields] AND "cutaneous"[All Fields]) OR "leishmaniasis, cutaneous"[All Fields] AND "placebo"[All Fields]). Finally, in the third strategy, studies with some arm of “no treatment” or placebo were searched for in the reference lists of all reviews identified by the first two strategies. The initial search was complemented by a manual search of the reference lists from the retrieved articles. Studies were considered eligible if they were presented in an original article and examined American patients with CL diagnosis treated with placebo or left untreated. There were no restrictions on the publication language, date of publication or study design. Studies involving non-human participants and studies with less than ten patients in the non-treatment arm were excluded. Studies using any substance with intrinsic activity in placebo arm were excluded. The full texts of the selected articles were read to confirm their eligibility and to extract the data.

Four investigators (GFC, TFO, PSS, and TKA) independently extracted the participant data, studies characteristics, predominant parasite species, interventions, and outcomes from the included reports using a standardized data collection form. When available, the follow-up length and relapse rate were also recorded. The main outcomes studied were clinical cure, defined as complete ulcer healing, and relapse and subsequent mucosal involvement rates.

The quality of the randomized studies was evaluated using the following criteria: 1) double-blind; 2) concealment of treatment allocation; 3) blinding of outcome assessment; and 4) intention-to-treat analysis. Concealment of treatment allocation was adequate if the patients and enrolling investigators could not predict assignment. Outcome assessment was considered blinded if the investigator who assessed the outcome had no knowledge of the treatment assignment. The analysis was performed according to the intention-to-treat principle, if all randomized patients were included in the analysis and maintained in their originally assigned groups. If there was not sufficient information to assess the quality of the study, it was deemed inadequate.

The timing of cure assessment after treatment varied significantly among studies: relatively early in some studies, while later in others. Considering that the time between the end of treatment and healing assessment can potentially influence cure rate, we established two cure rate occasions by pooling studies according to the time at which cure assessment was originally performed and by implementing the recommendations for the standardization of outcomes in CL trials [10]. After pooling the studies, two cure assessment time points were included in our analysis: a “initial cure”, assessed at approximately three months, and a “definitive cure”, assessed at 9 months after “no treatment” or placebo use. With the aim of gathering as much information as possible, even if the author had defined cure according to clinical assessment performed at a specific moment, if information was available at other moments of interest, they were included in our analysis.

The efficacy of therapy was assessed by clinical criteria in all studies. The definitions of clinical cure varied slightly between studies, with most studies requiring complete epithelialization of all lesions. Only one study defined cure as 80% or more of the ulcer area being re-epithelialized [11]. Some authors carried out parasitological cure assessment in addition to clinical
assessment [12–14]; however, when both outcomes (clinical and parasitological) were independently available, the parasitological findings were not considered in the cure outcome analysis (data not shown). In three studies [15–17], cure was assessed solely at the 6-month follow-up. For studies that performed “initial cure” assessment (at approximately 3 months of follow-up) and also presented the lesion evolution without treatment at 6–12 months of follow-up, the second assessment was also included in the cure outcome analysis. However, in many studies [11, 13, 14, 18, 19], patients whose lesions did not achieve healing were removed from the protocol and were treated with conventional drugs, making a “definitive cure” assessment unfeasible. In the majority of studies, patients were followed for approximately 6 to 12 months.

To standardize the cure criteria, even if the authors had considered a negative parasitological finding as criteria of cure, in our analysis, cure was considered exclusively according to clinical criteria. Similarly, some studies [12, 17] included no reactivation of any ulcer through 12 months of follow-up as an additional criteria for cure. As adopted in previous studies, to standardize the outcomes among studies, if a clinical assessment was available, cure was defined exclusively by the clinical criteria (re-epithelialization of the lesion at any given time), regardless of the subsequent observation of relapse.

Quantitative data synthesis
Comprehensive Meta-Analysis® software v.2.2.048 was used to perform the one-group meta-analysis of study arms using placebo or no treatment to estimate the pooled rates of spontaneous cure according to the intention-to-treat principle, irrespective of how the original study investigators analyzed the data. We used the inconsistency (I²) statistic to evaluate heterogeneity and Egger’s test to assess publication bias. For all cure and relapse rate analyses, a random model was chosen. To evaluate cure rate stratified by Leishmania species, we used a mixed effects analysis—a random effects model was used to classify the studies into each subgroup.

Results
The PubMed search identified 16 relevant articles. The LILACS database search identified two additional papers. Among the three search strategies performed in the PubMed database, the first one, which was the most wide, was the most sensitive and identified all 13 studies ultimately included in this review. The search strategy that included the “placebo” term was not as sensitive as the first search strategy. One possible explanation for this finding is that studies describing the evolution of untreated patients are not properly indexed. Third search strategy was useful to compare our results to those retrieved by others published reviews on the same topic. The results of the three searches are shown in a flowchart in S1 Fig. After exclusion based on titles and abstracts, 18 potentially relevant papers were selected for full text evaluation. Of them, 2 papers were excluded, because the same patients were described elsewhere [20, 21]; one study was a review [22] and the other included less than 10 patients in the placebo arm [23]. One additional study [24] was excluded, because the patients in the placebo arm were given a potentially active drug (1% lidocaine), which was not considered a genuine “vehicle control”. Thus, we included 13 studies [11–19, 25–28] that involved 352 patients presenting with localized CL who were followed after no therapy or placebo use (Table 1). No study included patients infected with HIV or presenting with other immunosuppressive diseases. All included studies were randomized trials, but they compared different treatment regimens and, in some of them, the patients who were untreated were those who refused therapy or were members of a “historical” control group. The methodological characteristics of the studies, namely the diagnostic, treatment arms (MA: meglumine antimoniate, SS: sodium stibugluconate, MBCL: paromomycin 15% + methylbenzethonium chloride, allopurinol + probenecid,
| Year, author        | Study arms (number of patients) | Study sample | Inclusion criteria                                                                 | Exclusion criteria                                                                                     | Follow-up (months) | Leishmania species characterization (% of patients) | Leishmania species | Cure criteria used                                                                 | Lost to follow-up |
|---------------------|---------------------------------|--------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------|------------------|-------------------------------------------------------------------------------------|------------------|
| 2013, Soto et al.   | MA intralesional (30), Cryotherapy (20), Placebo cream (30) | 80           | parasitological diagnosis (smears or biopsy, culture), ≥ 12 years of age, one ulcerative lesion ≤ 30 mm² resulting in a total lesion area of ≤ 900 mm² | previous anti-leishmanial therapy (< 3 months), mucosal lesions, concomitant diseases | 6                 | 42/80 (52.5%)                                      | L. braziliensis (36); L. guyanensis (2); L. amazonensis (2); L. lainsoni (2) | 100% reepithelialization within 6 months after the end of therapy | 3/80 (3.7%)       |
| 2004, Soto et al.   | Miltefosine (89); Placebo (44)  | 133          | parasitological diagnosis (smears, culture, biopsy, monoclonal antibody), ≥ 12 years of age | previous anti-leishmanial therapy (< 4 weeks), mucosal lesions, concomitant diseases | 6                 | 53/133 (39.8%)                                    | L braziliensis (29); L mexicana (17); L panamensis (7) | 100% reepithelialization within 6 months after the end of therapy | 8/133 (6%)        |
| 2002, Soto et al.   | New drug test # (33), Placebo (12) | 45           | parasitological diagnosis (smears, culture, biopsy, monoclonal antibody), total ulcer lesion size < 2000 mm², lymphadenopathy < 1 cm | severe disease; papular or nodular lesions; mucosal lesions, concomitant diseases | 6                 | 5/45 (11.1%)                                      | L. panamensis (5)     | 100% reepithelialization by the 6-month follow-up                                    | 8/45 (17.8%)      |
| 2001, Arana et al. | Paromomycin + MBCL (38), Placebo (38) | 76           | parasitological diagnosis (smears, culture), age between 10–60 years, (smears, culture) | > 4 lesions; lesion > 5 cm in diameter; previous anti-leishmanial therapy; mucosal lesions, concomitant diseases | 12                | not available                                      | not available     | 100% reepithelialization by the 13-week follow-up                                    | 8/76 (10.5%)      |
| 1997, Neva et al.   | Topical paromomycin + urea (23); Placebo (30) | 53           | parasitological diagnosis (culture)                                                | NA                                                                                                     | 5                 | 53/53 (100%)                                      | L. mexicana (18), L. chagasi (35) | 100% reepithelialization within 11 weeks after the end of therapy | 6/53 (11.3%)      |
| 1997, Velez et al.  | Allopurinol (60), Placebo (56); MA (66) | 182          | parasitological diagnosis (smears, culture), age between 6–60 years; body weight appropriate for height | Previous anti-leishmanial therapy, lesions close to the eyes; mucosal lesions, concomitant diseases, pregnancy | 12                | not available                                      | not available     | 100% reepithelialization within 3 months after the end of therapy with no relapse by the 12-month follow-up | 25/182 (13.7%)    |
| 1995, Martha et al. | Allopurinol + probenecid (30); SS (30); No therapy (15) | 75           | parasitological diagnosis (smears, culture, biopsy, monoclonal antibody)          | mucosal lesions, concomitant diseases                                                                | 12                | 26/75 (34.7%)                                    | L. panamensis (12); L. guyanensis (7); L. braziliensis (4); L. mexicana (1); L. amazonensis (2) | 100% reepithelialization by the 70-day follow-up | 13/75 (17.3%)     |

(Continued)
| Year, author | Study arms (number of patients) | Study sample | Inclusion criteria | Exclusion criteria | Follow-up (months) | Leishmania species characterization (% of patients) | Leishmania species | Cure criteria used | Lost to follow-up |
|--------------|--------------------------------|--------------|-------------------|-------------------|-------------------|-----------------------------------------------|------------------|------------------|------------------|
| 1993, Soto et al. | MA (23); Pentamidine (27), Itraconazole (20); No treatment (22) | 92 | parasitological diagnosis (smears, culture, biopsy, monoclonal antibody), age between 18–60 years | mucosal lesions, concomitant diseases, previous anti-leishmanial therapy | 12 | not available | not available | 100% reepithelialization within 1.5 months after the end of therapy | 6/92 (6.5%) |
| 1992, Martinez et al. | MA (33); Allopurinol+MA (35); Allopurinol (25), No treatment (17) | 110 | parasitological diagnosis (smears, culture, biopsy); lesions confined to the upper portion of the trunk or arms | allergy to antimony or allopurinol; pregnant or nursing, concomitant diseases, more than 20% above or below ideal weight | 12 | 110/110 (100%) | L. panamensis (110) | 100% reepithelialization and negative culture within 3 months after the end of therapy | not available |
| 1992, Navin et al. | SS (40); Ketoconazole (38), Placebo (40) | 120 | parasitological diagnosis (smears, culture), male gender | mucosal lesions, concomitant diseases, previous anti-leishmanial therapy | 13 | 97/120 (80.8%) | L. mexicana (32); L. braziliensis (63); both L. mexicana and L. braziliensis (2) | 100% reepithelialization by the 13-week follow-up | 7/120 (5.8%). |
| 1991, Guderian et al. | SS (30); Allopurinol +probenecid (30); No treatment (15) | 75 | parasitological diagnosis (smears, culture, biopsy, monoclonal antibody) | mucosal lesions, concomitant diseases, less than 6 months of follow-up | 1.5 * | 23/75 (30.7%) | L. panamensis (12); L. guyanensis (5); L. braziliensis (3); L. mexicana(3) | >80% reepithelialization by the 1-month follow-up | 14/75 (18.7%). |
| 1990, Navin et al. | MA (22); Localized Heat (22); Placebo (22) | 66 | parasitological diagnosis (smears, culture), lesions<25 cm² | lesions in ear, near the eye, on the finger; presence of unilateral lymphadenopathy; mucosal lesions, concomitant diseases, previous anti-leishmanial therapy | 12 | 53/66 (80.3%) | L. mexicana (13); L. braziliensis (40) | 100% reepithelialization by the 13-week follow-up | 3/66 (4.54%) |
| 1990, Saenz et al. | Ketoconazole (22); SS (19); Placebo (11) | 52 | parasitological diagnosis (smears, culture) | facial or mucosal lesions; concomitant disease | 3 | 38/52 (73.1%) | L. guyanensis (37); L. mexicana (1) | 100% reepithelialization by the 1-month follow-up | NA |
ketoconazole, miltefosine, cryotherapy, pentamidine, itraconazole and localized heat), inclusion, exclusion and cure criteria are shown in Table 1. In nine studies, the control group received a placebo, and in the remaining four studies, the control group received no treatment.

The patient characteristics are shown in S1 Table. Patient age ranged from 19 to 36 years; 88% of the patients were male, and most of them had less than three lesions localized in arms or legs. CL was diagnosed in all studies if patients had a compatible clinical illness and *Leishmania* was identified on Giemsa-stained smears, culture or biopsy. In a few studies, a positive monoclonal antibody test [11, 15, 16, 25, 28] was also considered to confirm *Leishmania* infection. Although all studies had required laboratory confirmation of the diagnosis of CL, the percentage of isolation of the *Leishmania* species across studies ranged from 11 to 100% of the patients (112 of 352, 32%). In three studies *Leishmania* species characterization was not performed.

The summarized cure rates according to the intention-to-treat analysis are shown in Table 2 and Figs 1 and 2. The "initial cure" was assessed at a median of 11.5 weeks of follow-up (range: 4.5 to 13 weeks of follow up) and "definitive cure" was assessed at a median of 9 months

| Author, year | Patients in placebo or “no treatment” arm (patients) | Initial cure (n/%) | Definitive cure (n/%) | Cure rate according to *Leishmania* species(n/%) | Relapse after cure (n/%) | Late mucosal involvement (n/%) |
|--------------|------------------------------------------------------|-------------------|----------------------|---------------------------------------------|------------------------|-------------------------------|
| Soto et al., 2013 | 30 | 6/30 (20) | 4/30 (13.3) | Not informed | 2/6 (33.3) | Not available |
| Soto et al., 2004 | 44 | Not informed | 13/44 (29.5) | 1/13 (7.7) *L. braziliensis* 1/3 (33.3) *L. mexicana* | 1/13 (7.7) | Not available |
| Soto et al., 2002 | 12 | Not informed | 5/12 (41.7) | Not available | Not available | Not available |
| Arana et al., 2001 | 38 | 18/38 (47.4) | Not available | Not available | 0/13 (0) | Not available |
| Neva et al., 1997 | 30 | 1/30 (4.5) | Not available | 0/8 (0) *L. mexicana* 1/22 (4.5) *L. chagasi* | Not available | Not available |
| Velez et al., 1997 | 56 | Not available | 17/56 (30.4) | Not available | 0/17 (0) | 1/56 (1.8) |
| Martha et al., 1995 | 15 | 9/15 (60) | Not available | Not available | 0/5 (0) | Not available |
| Soto et al., 1993 | 22 | 4/22 (18.2) | Not available | Not available | 2/4 (50) | Not available |
| Martinez et al., 1992 | 17 | 2/17 (11.7) | 0/17 (0) | 0/17 (0) *L. panamensis* | 2/2 (100) | Not available |
| Navin et al., 1992 | 40 | 17/40 (4.5) | Not available | 1/15 (6.7) *L. braziliensis* 8/16 (50) *L. mexicana* | 3/17 (17.6) | Not available |
| Guderian et al., 1991 | 15 | 9/15 (60) | Not available | Not available | 0/9 (0) | Not available |
| Navin et al., 1990 | 22 | 6/22 (27.3) | Not available | 0/11 (0) *L. braziliensis* 5/7 (71) *L. mexicana* | 0/6 (0) | Not available |
| Saenz et al., 1990 | 11 | 0/11 (0) | Not available | Not available | Not available | Not available |

doi:10.1371/journal.pone.0149697.t002
of follow-up (range: 6 to 12 months of follow-up). Relapse was assessed in patients who were treated and were considered cured. Of note, the study presenting with the highest spontaneous cure rate [11] was the one that used a less stringent criterion for cure (unlike all other studies in which complete re-epithelialization was the requirement, in that study, reepithelization equal to or above 80% of the ulcer area was considered sufficient for cure establishment). Considering the current cure definition of complete reepithelization [10] and the requirement of standardization of criteria for combining the results of multiple studies, we excluded this discrepant study from the final analysis. Using placebo or no treatment, the initial cure rate was 26% (CI95%: 16 to 40%, heterogeneity I² = 70), and the definitive cure rate was 26% (CI95%:16 to 38%, heterogeneity I² = 48). In addition, despite the smaller number of patients with species characterization available (only 112 of 352), a significantly lower cure rate was observed for *L. braziliensis* infection (6.4%, CI95%:0.2 to 20%) than for *L. mexicana* infection (44%, CI95%:19 to 72%), p = 0.002.

![Initial (A) and definite (B) cure rates observed in American cutaneous leishmaniasis patients without treatment or with placebo use.](doi:10.1371/journal.pone.0149697.g001)

![Cure rate observed in American cutaneous leishmaniasis patients without treatment or with placebo use according to *Leishmania* species.](doi:10.1371/journal.pone.0149697.g002)
The relapse rate was 20% (CI95%: 9.2 to 38.9%) and is shown in Fig 3. The relapse rate is the percentage of patients with worsening skin lesions after initial healing and was usually assessed at approximately 12 months of follow-up.

The study quality assessment is shown in Table 3. In general, the studies included adequate numbers of patients and CL was invariably parasitologically confirmed. These patients were largely representative of the source populations. However, in two studies [11,12], in the placebo or no therapy arm, patients were not randomly allocated, which generates an important selection bias.

### Discussion

Our main result was the very low spontaneous (6%) healing rate observed in American CL caused by *L. braziliensis*. This CL cure rate significantly contrasts with that described with antimonial derivatives in the Americas (71.3–91.4%) [6]. Considering all patients gathered in this study, the spontaneous cure rate was also low (26%); however, there was high heterogeneity across studies (IC95%: 16–40%), preventing us from expanding this conclusion to all species that cause CL in the Americas.

Although we have made an extensive review by combining several search strategies, our analysis includes few studies and a relatively small number of patients thus hampering a stratified analysis of cure by *Leishmanias* species. Another limitation is the bias represented by the

| Study name            | Statistics for each study | Event rate and 95% CI |
|-----------------------|---------------------------|-----------------------|
|                       | Event rate | Lower limit | Upper limit |                      |
| Soto et al., 2013     | 0.333      | 0.084       | 0.732       |                      |
| Soto et al., 2004     | 0.077      | 0.011       | 0.391       |                      |
| Arana et al., 2001    | 0.036      | 0.002       | 0.384       |                      |
| Martha et al., 1995   | 0.083      | 0.005       | 0.622       |                      |
| Soto et al., 1993     | 0.500      | 0.123       | 0.877       |                      |
| Martinez et al., 1992 | 0.833      | 0.194       | 0.990       |                      |
| Navin et al., 1992    | 0.176      | 0.058       | 0.427       |                      |
| Navin et al., 1990    | 0.071      | 0.004       | 0.577       |                      |

Heterogeneity I² = 32

Fig 3. Relapse rate observed in American cutaneous leishmaniasis patients without treatment or with placebo use who presented with initial ulcer healing.

doi:10.1371/journal.pone.0149697.g003
### Table 3. Study quality evaluation.

| Author, year | Double-blind | Concealment of treatment allocation | Blinding of outcome assessment | Intention-to-treat analysis | Comments |
|--------------|--------------|-------------------------------------|-------------------------------|----------------------------|----------|
| Saenz et al., 1990 | No | No * | No | Yes | * Randomization generation domain not informed. The placebo group was sequentially recruited one year after the recruitment of the treatment groups. Three patients were not randomized and received ketoconazole. |
| Navin et al., 1990 | No | Yes* | No | Yes | *Randomization generation domain not informed |
| Guderian et al., 1991 | No | Yes* | No | No | *Randomization generation domain not informed |
| Martinez et al., 1992 | No | Yes* | No | Yes | *Randomization generated by a computer program. Patients who agreed to participate but refused to receive injections received allopurinol. Patients not eligible for treatment were allocated to the control group. These groups were not randomized but were self-selected. |
| Navin et al., 1992 | No | Yes* | Yes | No | *Randomization generated by a computer program |
| Martha et al., 1995 | No | Yes* | No | No | *Randomization generation domain not informed |
| Soto et al., 1993 | No | Yes* | No | No | *Numerical sequence randomization. Randomization was not uniform for all patients included. Twenty of 92 patients were randomized to one of the treatment arms, without the placebo option. |
| Neva et al., 1997 | Yes | Yes | Yes | Yes | Randomization generated by a computer program |
| Velez et al., 1997 | Yes* | Yes** | Yes*** | Yes | *Only the allopurinol and placebo groups were double-blind, not the Glucantime group. **Randomization generation domain not informed. ***Yes to placebo and allopurinol groups, not mentioned for Glucantime group. |
| Arana et al., 2001 | Yes | Yes | Yes | No | Tubes randomly numbered by industry |
| Soto et al., 2002 | No | Yes* | Yes | Yes | *Randomization generation domain not informed. |

(Continued)
imperfect randomization of patients. Despite these limitations, this review raises necessary reflection about ethical aspects in CL trials.

The three most common reasons used to justify the use of a placebo arm in American CL studies are as follows: 1) the doubtful cure rate obtained with pentavalent antimonial drugs, as the current evidence of their efficacy is not sufficiently strong, mainly because of the weakness of clinical trials; 2) the non-systematic observation of spontaneous healing in CL, which can “contribute” to the cure rate outcome of a investigated treatment, resulting on an over-estimated cure rate and 3) the benign nature of the damage caused by delayed treatment or no treatment or placebo, frequently considered to be reversible and “not serious” harm.

Considering the previously published systematic reviews about the efficacy of the antimony derivatives and the results presented here, the first two justifications for the use of a placebo arm in American CL studies can be considered, in the present state of knowledge, to be negated as follows: the available therapies normally prescribed have recognized efficacy, and the spontaneous cure rate for CL is low in the Americas. Therefore, what still needs to be examined is the magnitude of harm caused by the disease or how much suffering patients can ethically be exposed to by delaying appropriate treatment with placebo administration.

There are many reasons for the historical use of placebo, including the endorsement provided by regulatory bodies in the interests of accuracy [29]. The most efficient way to eliminate the effect of placebo in the final statistical analysis is random allocation of patients into a placebo concurrent control arm. Although this approach is scientifically sound, ethical concerns arise under specific conditions that outweigh the alleged benefits of this protocol design.

There is agreement that the use of placebo or another form of untreated control is almost always unethical when a therapy is available that has been shown to improve survival or decrease serious morbidity. However, for conditions in which the treatment does not affect the patient’s long-term survival, as is the case for CL, this discussion becomes enormously complex and causes division among researchers. It is well noted that the Helsinki Declaration accepts placebo-controlled trials since its 2008 revision; a decision that was maintained in the 2013 version [30]. This World Medical Association position is far from being generally accepted, and the Brazilian National Health Board is against these two revisions and keeps the position that placebo-controlled trials are unethical whenever they are used to evaluate new treatments for conditions when proven effective treatments exist [31]. In countries where the Helsinki Declaration is adopted, researchers and research organizations should observe the two conditions that it states as necessary for the use of a placebo or no intervention arm: the existence of “compelling and scientifically sound methodological reasons” and “the patients who receive any intervention less effective than the best proven one, placebo, or no intervention will not be subject to additional risks of serious or irreversible harm”. According to Emanuel and Miller (2001) [32], a placebo-controlled trial has a sound scientific rationale if the following criteria are met: “there is a high placebo-response rate; the condition is typically characterized by a

| Author, year | Double-blind | Concealment of treatment allocation | Blinding of outcome assessment | Intention-to-treat analysis | Comments |
|--------------|--------------|------------------------------------|-------------------------------|--------------------------|----------|
| Soto et al., 2004 | Yes          | No*                                | Yes                           | Yes                      | * Randomization domain not informed. |
| Soto et al., 2013    | No           | Yes*                               | No**                          | Yes                      | * Deck of cards randomization. **Information not available |
waxing-and-waning course, frequent spontaneous remissions, or both; and existing therapies
are only partly effective or have very serious side effects; or the low frequency of the condition
means that an equivalence trial would have to be so large that it would reasonably prevent ade-
quate enrollment and completion of the study”. In a simple analysis, it is noted that the above
criteria cannot be fully applied to CL and the “compelling methodological reasons” that could
justify this choice are at least questionable. Furthermore, even when these methodological cri-
teria are met, the risk of using a placebo control should also be evaluated according to several
ethical criteria. The Helsinki Declaration states that research participants in the placebo group
“should not be substantially more likely than those in the active-treatment group to die; to
have irreversible morbidity or disability or to suffer other harm; to suffer reversible but serious
harm; or to experience severe discomfort” [33]. Based on that statement, Temple and Ellenberg
[34] claimed that the use of a placebo control is ethical if the research participants who receive
the placebo will experience “no permanent adverse consequence”, if there is only a risk of “tem-
porary discomforts,” or if they “will not be harmed.” Ultimately, it is notable that “scientific
rationale criteria” for placebo use permit suffering of the study participants that is not negligi-
ble, and the interpretation of these “no equivalent principles” is a very arduous task. In addition,
parameters, such as the seriousness of the damage and the degree of discomfort, are too
subjective and personal to allow for arbitration.

It is also useful to review the risks addressed by the U.S. Federal regulations [32], which can
be used to categorize the risks of damage to the subjects into one of three types: physical, psy-
chological, and informational. Furthermore, the proponents of placebo controls focus exclu-
sively on physical harm. It is important to note that skin lesions are a common cause of social
isolation, disruption of relationships and loss of employment. These social harms lead to emo-
tional damage, both of which are either not considered or are dismissed. However, as noted by
Emanuel and Miller [32], in a contradictory manner, “psychological and social harms are
invoked to justify the value of the research”.

Another important topic linked to the placebo discussion is the toxicity related to antimo-
nial derivatives, an argument that is sometimes used to promote placebo use. While we empha-
size that the toxicity of antimony derivatives is not negligible and that, in CL, the “best proven
treatment” is a “non-optimal treatment”, we also recognize that unexpected adverse effects are
very rare in young patients without comorbidities, who normally compose the study groups of
CL studies, and that monitored antimony use can avoid much of the serious adverse events
reported [35]. It is also important to note that antimony derivatives are considered to have
high evidence quality in the treatment of CL and are strongly recommended in the guide pro-
duced by the Pan American Health Organization for the treatment of leishmaniasis [36]. Obvi-
ously, there are other operational implications of using antimony derivatives: the use of an
antimony derivative under close adherence to the recommended precautions as comparator
arm in clinical CL trials potentially restricts recruitment, and the study may require increased
time and funds.

Finally, in American CL, this discussion brings up another important and unclear point:
mucosal involvement is a late complication that is mainly related to L. braziliensis infection but
also to species found in the Americas, including L. (V.) panamensis, L. (V.) guyanensis and L
(L) amazonensis [37]. Unfortunately the studies available and included in this review did not
perform a sufficiently long follow-up preventing us to conclude about the mucosal involvement
risk. A detailed analysis of this issue was not the purpose of the present discussion; however,
despite reports of this complication even after appropriate therapy, the risk seems to increase,
more than the risks of any other complications, in patients who are not adequately treated
[38, 39].
Considering these unknown elements and the risks embedded in each study design, research planning, particularly in the CL field, requires deep ethical reflection. It is certainly necessary to review the recommendations for clinical trials focused on American CL, especially when the infectious agent is *L. braziliensis*. Based on a low spontaneous cure rate observed in non-treated patients and our above reflections, we believe that for clinical studies of CL in the Americas, there is a sufficient basis for discouraging the use of a placebo or non-treatment arm. Patients need to be protected from unethical exposures to morbidity, pain and social stigmatization and, instead, should be offered immediate and adequate treatment.

**Supporting Information**

S1 Fig. Review search strategy. (TIF)

S1 Table. Population characteristics of the placebo or no therapy arm. (DOCX)

S1 Text. PRISMA checklist. (DOC)

**Author Contributions**

Conceived and designed the experiments: GFC MRS AR. Performed the experiments: GFC MRS TOF PSS TKA AR. Analyzed the data: GFC MRS TOF PSS TKA AR. Wrote the paper: GFC MRS TOF PSS TKA AR.

**References**

1. Yamey G. The world's most neglected diseases BMJ 2002; 325:352.
2. González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis. [Guideline Research Support, Non-U.S. Gov't Review]. 2010 Aug 15; 51(4):409–419. doi: 10.1086/655134 PMID: 20624067
3. World Health Organization (WHO). Report of the Fifth Consultative Meeting on HIV/Leishmania Co-infection. Addis Ababa, 20–22 March 2007. Available: http://www.who.int/leishmaniasis/resources/Leishmaniasis_hiv_co-infection5.pdf
4. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009 Apr 15;(2): CD004834. doi: 10.1002/14651858.CD004834.pub2 PMID: 19370612
5. Reveiz L, Maia-Elkhoury AN, Nicholls RS, Romero GA, Yadon ZE. Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. PLoS One. [Review]. 2013; 8(4): e61843. doi: 10.1371/journal.pone.0061843 PMID: 23637917
6. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Amato Neto V. Treatment of New World cutaneous leishmaniasis—a systematic review with a meta-analysis. Int J Dermatol. [Meta-Analysis] 2008 Feb; 47(2):109–124. doi: 10.1111/j.1365-4632.2008.03417.x PMID: 1812479
7. Bailey MS, Lockwood DN. Cutaneous leishmaniasis. Clin Dermatol. [Review]. 2007 Mar-Apr; 25 (2):203–211. PMID: 17350500
8. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. [Consensus Development Conference Guideline Research Support, Non-U.S. Gov't] 2009 Jul 21; 6(7):e1000100. doi: 10.1371/journal.pmed.1000100 PMID: 19621070
9. Higgins JPT GSe. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration.
10. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis. 2013; 7(3):e2130. doi: 10.1371/journal.pntd.0002130 PMID: 23556016
11. Guderian RH, Chico ME, Rogers MD, Pattishall KM, Grogl M, Berman JD. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. Am J Trop Med Hyg. [Clinical Trial Randomized Controlled Trial]. 1991 Jul; 45(1):92–97. PMID: 1651060

12. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med. [Clinical Trial Comparative Study Randomized Controlled Trial]. 1992 Mar 12; 326(11):741–744. PMID: 1738379

13. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. [Clinical Trial Comparative Study Randomized Controlled Trial]. 1990 Aug; 89(2):147–155. PMID: 2166429

14. Navín TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg. [Clinical Trial Randomized Controlled Trial]. 1990 Jan; 42(1):43–50. PMID: 2405727

15. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2004 May 1; 38(9):1266–1272. PMID: 15127339

16. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nichols RS, Padilla JR, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg. [Clinical Trial Clinical Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. 2002 Feb; 66(2):147–151. PMID: 12135295

17. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 1997 Feb 1; 126(3):232–236. PMID: 9027276

18. Navín TR, Arana BA, Arana FE, Berman JD, Chacon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. [Clinical Trial Comparative Study Randomized Controlled Trial Research Support, U.S. Gov't, Non-P.H.S.]. 1992 Mar; 165(3):528–534. PMID: 1311351

19. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2001 Nov; 65(5):466–470. PMID: 11716099

20. Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA. Velez Bernal ID. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg. [Clinical Trial Research Support, Non-U.S. Gov't]. 1998 Dec; 59(6):889–892. PMID: 9886195

21. Herwaldt BL, Arana BA, Navín TR. The natural history of cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg. [Clinical Trial Research Support, Non-U.S. Gov't]. 1998 Dec; 59(6):889–892. PMID: 9886195

22. Soto J, Berman J. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg. [Review]. 2006 Dec 10; 100 Suppl 1:S34–40. PMID: 16930649

23. Lopez-Jaramillo P, Ruano C, Rivera J, Teran E, Salazar-irigoyen R, Esplugues JV, et al. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet. [Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't]. 1998 Apr 18; 351(9110):1176–1177. PMID: 9643692

24. Scorza YYJV. Intralesional chemotherapy with meglumine plus lidocaine of localized cutaneous leishmaniasis in Argentina. Clin Infect Dis. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 1997 May; 24(5):744–749. PMID: 9373659

25. Martha Chico; Rodrigo Armijos; José Racines TM, Guderian Ronald H. Evaluación del ribósido de allopurinol contra la leishmaniasis cutánea ecuatoriana. Biomedica (Bogotá). 1995; 15(3):116–122.
30. 64th World Medical Association. General Assembly Fortaleza, Brazil, October 2013. Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects. JAMA 2013; 310(20):2191–2194. doi: 10.1001/jama.2013.281053 PMID: 24141714

31. Conselho Nacional de Saúde. 240ª Reunião Ordinária. RESOLUÇÃO N° 466 2012. Diário Oficial da União. 2012. Diário Oficial da União: 12, Seção 1: 59. Available: http://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf

32. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials—a middle ground. N Engl J Med. 2001 Sep 20; 345(12):915–919. PMID: 11565527

33. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277:925–926. PMID: 9062334

34. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000 Sep 19; 133(6):455–463. PMID: 10975964

35. Wise ES, Armstrong MS, Watson J, Lockwood DN. Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]. PLoS Negl Trop Dis. 2012; 6(6):e1688. doi: 10.1371/journal.pntd.0001688 PMID: 22745840

36. Leishmaniasis en las Américas: recomendaciones para el tratamiento. Catalogación en la Fuente, Organización Panamericana de la Salud. Washington DCO, 2013.

37. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther. [Research Support, Non-U.S. Gov't Review]. 2010 Apr; 8(4):419–433. doi: 10.1586/eri.10.19 PMID: 20377337

38. Blum J, Lockwood DN, Visser L, Harms G, Bailey MS, Caumes E, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health. 2012 Sep; 4(3):153–163. doi: 10.1016/j.inhe.2012.06.004 PMID: 24029394

39. Machado-Coelho GL, Caiaffa WT, Genaro O, Magalhaes PA, Mayrink W. Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. [Research Support, Non-U.S. Gov't]. 2005 Jan; 99(1):55–61. PMID: 15550262